Market Research Logo

Global Atrial Fibrillation Market 2015-2019

Global Atrial Fibrillation Market 2015-2019

About Atrial Fibrillation

According to the NHLBI of the NIH in the US, atrial fibrillation is one of the commonest type of arrhythmia. Atrial fibrillation is similar to another type of arrhythmia of the heart, superventricular tachycardia. The chief difference between these two types of arrhythmia is the consistency of the beats. In superventricular tachycardia, the heart beats are regular and at a very fast pace. Patients with atrial fibrillation experience fast and irregular heartbeats. In patients with atrial fibrillation, electrical signals travel rapidly in an uncontrolled way, which causes convulsion, palpitation or contraction in the atria of the heart. Blood is accumulated inside the atrial chambers, instead of flowing to the ventricular chambers. In this case, blood is not pumped into the ventricles fully. Also, the quantity of blood pumped out of the ventricles to the body is irregular and centered on the arbitrary atrial strokes. This can lead to the formation of blood clot in the atria. Stroke occurs in case the clot moves to the brain, which can cause death of an individual. In atrial fibrillation, the ventricles might beat for 100 to 175 times per minute, which is a stark contrast to the normal heart rate of 60 to 100 beats per minute. Atrial fibrillation is more common in older people and is detected using an ECG reading to find out the abnormalities of the electric signal. Some of the symptoms of atrial fibrillation are rapid and irregular heartbeat, palpitations, dizziness, sweating, chest pain, breathlessness, fatigue, and sometimes loss of consciousness.

TechNavio's analysts forecast the Global Atrial Fibrillation market to grow at a CAGR of 11.05 percent over the period 2014-2019.

Covered in this Report

This report covers the present scenario and the growth prospects of the Global Atrial Fibrillation market for the period 2015-2019. To calculate the market size, the report considers the revenue generated from the sales of various drugs such as anti-arrythmics and anticoagulants used in the treatment of atrial fibrillation.The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the Global Atrial Fibrillation market. The vendor landscape section includes a market share analysis of the major vendors along with the performances of their product portfolios. In addition, it discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends that are emerging in the market.

TechNavio's report, Global Atrial Fibrillation Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Atrial Fibrillation market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions

  • Americas
  • APAC
  • EMEA
Key Vendors
  • Boehringer Ingelheim
  • Janssen Pharmaceuticals
  • Sanofi
Other Prominent Vendors
  • ARCA Biopharma
  • Armetheon
  • Baxter
  • Bristol-Myers Squibb
  • ChanRx
  • Daiichi Sankyo
  • Gilead Sciences
  • HUYA Biosciences
  • Menarini
  • Pfizer
  • Pierre Fabre
  • Servier
  • Xention
Market Driver
  • Growing Patient Base
  • For a full, detailed list, view our report
Market Challenge
  • High Cost of Therapy
  • For a full, detailed list, view our report
Market Trend
  • Shifting Focus on Emerging Markets
  • For a full, detailed list, view our report
Key Questions Answered in this Report
  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


Press Release

TechNavio Announces the Publication of its Research Report – Global Atrial Fibrillation Market 2015-2019

TechNavio recognizes the following companies as the key players in the Global Atrial Fibrillation Market: Boehringer Ingelheim GmbH, Janssen Pharmaceuticals Inc. and Sanofi SA.

Other Prominent Vendors in the market are: ARCA Biopharma, Armetheon, Baxter, Bristol-Myers Squibb, ChanRx, Daiichi Sankyo, Gilead Sciences, HUYA Biosciences, Menarini, Pfizer, Pierre Fabre, Servier and Xention.

Commenting on the report, an analyst from TechNavio’s team said: “The growing focus on emerging markets by drug manufacturers is one key trend witnessed in the market. Vendors are increasingly focusing on emerging markets owing to the lower production costs and the presence of lenient regulatory guidelines. Lenient regulatory guidelines, low manufacturing costs, skilled labor, and limited competition in the market are some of the factors that result in a decrease in the developmental costs of medical devices and an increase in the profit margins of manufacturers.”

According to the report, an increase in the patient population is one of the major factors propelling the growth of the market. The high prevalence of atrial fibrillation in patients worldwide, especially among people aged 60 and above, leads to an increase in the treatment-seeking patient population and increased consumption of medicines.

Further, the report states that the high cost of treatment is one of the major challenges hindering the growth of the market. The drugs that are used in the treatment of the disease are expensive and, hence, there is a poor response from patients in terms of compliance and acceptability.

Companies Mentioned

Boehringer Ingelheim, Janssen Pharmaceuticals, Sanofi, ARCA Biopharma , Armetheon, Baxter, Bristol-Myers Squibb, ChanRx , Daiichi Sankyo, Gilead Sciences, HUYA Biosciences, Menarini, Pfizer, Pierre Fabre, Servier, Xention

  • Executive Summary
  • List of Abbreviations
  • Scope of the Report
    • Market Overview
    • Product Offerings
  • Product Profiles
    • Pradaxa/Prazaxa
      • Xarelto
      • Multaq
  • Market Research Methodology
    • Market Research Process
    • Research Methodology
      • Table Market Research Methodology
  • Introduction
  • Disease Overview
    • Understanding the Disease
    • Classification
      • Table Types of Atrial Fibrillation
    • Pathophysiology
    • Causes
      • Table Risk Factors Associated with Atrial Fibrillation
    • Epidemiology
    • Management
      • Table Management of Atrial Fibrillation
    • Economic Burden
      • Table Economic Burden of Atrial Fibrillation
  • Market Landscape
    • Market Overview
    • Market Size and Forecast
      • Table Global Atrial Fibrillation Market 2014-2019 (US$ million)
      • Table Challenges and Drivers of Global Atrial Fibrillation Market
    • Five Forces Analysis
  • Market Segmentation by Class of Drug
    • Table Segmentation of Global Atrial Fibrillation Market by Class of Drug
    • Anticoagulants
      • Anti-arrythmics
        • Table Segmentation of Anti-arrythmics
  • Geographical Segmentation
    • Table Segmentation of Global Atrial Fibrillation Market by Geography 2014
  • Buying Criteria
    • Table Buying Criteria in Global Atrial Fibrillation Market 2014
  • Market Growth Drivers
    • Table Growth Drivers of Global Atrial Fibrillation Market
    • Table Global Population Aged 60 and Above 2010-2020
    • Table Global Prevalence of Atrial Fibrillation 2006-2016 (million)
  • Drivers and their Impact
    • Table Drivers and their Impact on Global Atrial Fibrillation Market by Key Customer Category 2014
    • Table Drivers and their Impact on Global Atrial Fibrillation Market by Geography 2014
  • Market Challenges
    • Table Challenges in Global Atrial Fibrillation Market
  • Impact of Drivers and Challenges
  • Market Trends
    • Table Trends in Global Atrial Fibrillation Market
  • Trends and their Impact
  • Vendor Landscape
    • Competitive Scenario
      • Key News
      • Mergers and Acquisitions
    • Market Share Analysis 2014
      • Table Global Atrial Fibrillation Market Share Analysis 2014
      • Boehringer Ingelheim
      • Sanofi
      • Janssen Pharmaceuticals
    • Other Prominent Vendors
  • Key Vendor Analysis
    • Boehringer Ingelheim
      • Key Facts
      • Business Overview
      • Business Segmentation by Revenue 2013
        • Table Boehringer Ingelheim: Business Segmentation by Revenue 2013
      • Business Segmentation by Revenue 2012 and 2013
        • Table Boehringer Ingelheim: Business Segmentation by Revenue 2012 and 2013 (US$ million)
      • Geographical Segmentation by Revenue 2013
        • Table Boehringer Ingelheim: Geographical Segmentation by Revenue 2013
      • Business Strategy
      • Recent Developments
      • SWOT Analysis
    • Janssen Pharmaceuticals
      • Key Facts
      • Business Overview
      • Recent Developments
      • SWOT Analysis
    • Sanofi
      • Key Facts
      • Business Description
      • Business Segmentation
        • Table Sanofi SA: Business Segmentation
      • Revenue by Business Segmentation
        • Table Sanofi SA: Revenue by Business Segmentation 2013
      • Revenue Comparison 2012 and 2013
        • Table Sanofi SA: Revenue by Business Segmentation 2012 and 2013 (US$ million)
      • Sales by Geography
        • Table Sanofi SA: Sales Revenue by Geographical Segmentation 2013
      • Business Strategy
      • Key Developments
      • SWOT Analysis
  • Other Reports in this Series

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report